Chimeric antigen receptor T in the treatment of multiple myeloma – state of the art and future directions

2020 ◽  
Vol 51 (3) ◽  
pp. 120-124
Author(s):  
Dominik Dytfeld
Keyword(s):  
Multiple Myeloma ◽  
Chimeric Antigen Receptor ◽  
Cellular Therapy ◽  
New Technology ◽  
Phase 1 ◽  
Antigen Receptor ◽  
New Drugs ◽  
Adoptive Cellular Therapy ◽  
B Cell Maturation ◽  
Complexity Cost

AbstractIn spite of the introduction of several new drugs in the last 10 years, multiple myeloma (MM) remains incurable. Thus, an adoptive cellular therapy using chimeric antigen receptor T (CART), a strategy to increase the frequency of tumor-directed and functionally active T cells targeting antigens present on the cancer cell, might change the treatment in MM as it did in lymphoma and ALL. There are several targets for CART therapy in MM on different levels of development, which are discussed in the manuscript. B-cell maturation antigen (BCMA) being tested in the studies of phase 1–2 is the most promising, but so far CART has not been approved in the cure of MM and remains an experimental approach. The hematological society is facing a new technology which with its potential ability to cure MM, in spite of its complexity, cost, and toxicity, will definitely and soon change the landscape of myeloma in Europe and world-wide.

scholarly journals Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

2019 ◽  
Vol 10 ◽  
Author(s):  
Marijke Timmers ◽  
Gils Roex ◽  
Yuedi Wang ◽  
Diana Campillo-Davo ◽  
Viggo F. I. Van Tendeloo ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cell ◽  
Cell Therapy ◽  
B Cell ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Cell Maturation ◽  
T Cell Therapy ◽  
B Cell Maturation ◽  
B Cell Maturation Antigen

scholarly journals B‐cell maturation antigen‐specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives

2020 ◽  
Vol 147 (8) ◽  
pp. 2029-2041 ◽  
Author(s):  
Leopold Sellner ◽  
Fuli Fan ◽  
Nicola Giesen ◽  
Maria‐Luisa Schubert ◽  
Hartmut Goldschmidt ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cells ◽  
B Cell ◽  
Clinical Experience ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Cell Maturation ◽  
Future Perspectives ◽  
B Cell Maturation ◽  
B Cell Maturation Antigen

scholarly journals Chimeric antigen receptor T cell therapies for multiple myeloma

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Chao Wu ◽  
Lina Zhang ◽  
Qierra R. Brockman ◽  
Fenghuang Zhan ◽  
Lijuan Chen
Keyword(s):  
Multiple Myeloma ◽  
T Cell ◽  
Cell Therapy ◽  
Chimeric Antigen Receptor ◽  
New Technologies ◽  
Unmet Need ◽  
Antigen Receptor ◽  
New Drugs ◽  
T Cell Therapy ◽  
Car T

AbstractMultiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies. There is an unmet need to develop novel therapies for refractory/relapsed MM. In the past few years, chimeric antigen receptor (CAR)-modified T cell therapy for MM has shown promising efficacy in preclinical and clinical studies. Furthermore, the toxicities of CAR-T cell therapy are manageable. This article summarizes recent developments of CAR-T therapy in MM, focusing on promising targets, new technologies, and new research areas. Additionally, a comprehensive overview of antigen selection is presented along with preliminary results and future directions of CAR-T therapy development.

scholarly journals Chimeric antigen receptor T cell therapy comes to clinical practice

2019 ◽  
Vol 27 (S2) ◽  
Author(s):  
D. Wall ◽  
J. Krueger
Keyword(s):  
T Cells ◽  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Cellular Therapy ◽  
Lymphoblastic Leukemia ◽  
Antigen Receptor ◽  
Adoptive Cellular Therapy ◽  
T Cell Therapy ◽  
Non Hodgkin Lymphoma ◽  
Car T

Adoptive cellular therapy with chimeric antigen receptor T cells (car-ts) has recently received approval from Health Canada and the U.S. Food and Drug Administration after remarkable and durable remissions were seen in children with recurrent or refractory leukemia and adults with non-Hodgkin lymphoma—responses that were so impressive that a shift in the paradigm of care has now occurred for children with acute lymphoblastic leukemia.    The concept behind car-t immunotherapy is that modification of a patient’s own T cells to facilitate their localization to the cancer cell, with subsequent activation of the T cell effector mechanism and proliferation, will result in targeted killing of cancer cells. The car-ts are a novel drug in that the starting material for the manufacture of the car-t product comes from the patient, whose viable T cells are then genetically modified. Thus, collaboration is needed between the pharmaceutical companies, which must meet good manufacturing standards for each patient’s unique product, and the treating sites. For regulators and health authorities, this new class of drugs requires new paradigms for assessment and approval. Treatments with car-ts require that institutions address unique logistics requirements and management of novel toxicities.    The Hospital for Sick Children has had early experience with both the licensing of clinical trials and the introduction of the first commercial product. Here, we provide an overview of basic concepts and treatment, with caveats drawn from what we have learned thus far in bringing this new therapy to the clinical front line.

Sign in / Sign up

Export Citation Format

Share Document